NCT00091793View on ClinicalTrials.gov

Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis

PHASE3CompletedINTERVENTIONAL
Enrollment

332

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

February 28, 2009

Study Completion Date

March 31, 2009

Conditions
Postmenopausal Osteoporosis
Interventions
DRUG

AMG 162

60 mg/mL denosumab given day 1, month 6, month 12 and month 18

DRUG

Placebo

Placebo given at day 1, month 6, month 12 and month 18

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT00091793 - Study to Evaluate AMG 162 in the Prevention of Postmenopausal Osteoporosis | Biotech Hunter | Biotech Hunter